Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood tests could speed up disease detection

NCT ID NCT05568966

Diagnosis Sponsor: LumiraDx UK Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 2 times

Summary

This study collects blood samples from 20,000 adults with conditions like infections, heart disease, or kidney issues. Researchers will use these samples to develop and fine-tune new diagnostic tests that can deliver results quickly at the point of care. The goal is to make disease monitoring faster and easier for both doctors and patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to faster, more accessible diagnostic tests for conditions like infections and heart disease, improving early detection and monitoring.
What could go wrong
This is an early-stage sample collection study, not a treatment trial. The new tests may not prove accurate enough or may not be developed into usable devices.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2022

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients will include those presenting at a medical unit (including but not limited to A\&E departments, hospital wards, or out-patient clinics) to their care team, in order to obtain a range of values for research of the new biomarkers on the LumiraDx system. Participants will include those who are expected to have (but are not limited to) biomarkers for diseases areas including embolism, infection or inflammation, cardiovascular, and renal cohorts.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Subject 18 years of age. * Willing and able to provide written informed consent and comply with study procedures. * Patients attending a definitive care team with research capabilities which has been enroled in this collection study. * Patients who can read and understand written English. * The subject must present as one of the following cohorts: 1. Group A - Embolism Cohort - Patients presenting with symptoms indicative of thromboembolic events. 2. Group B - Infection or Inflammation Cohort - Patients presenting with symptoms indicative of infection or inflammatory disorders. 3. Group C - Cardiovascular Cohort - Patients presenting with symptoms indicative of heart failure or acute coronary syndrome. 4. Group D - Renal Cohort - Patients presenting with symptoms indicative of renal disorders. 5. Group E - Other Cohort. - Patients who are not eligible for any of the above groups. Exclusion Criteria * Subject \<18 years of age. * Vulnerable populations deemed inappropriate for the study by the sites Principal Investigator. * Patients who have previously been enroled in any LumiraDx NOVEL study in the past 3 months and re-entry would breach the 24mL and or 6 fingersitck maximums.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Embolism and Thrombosis Infections infectious disease Inflammation inflammatory disease kidney disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular Embolism and thrombosis Infections Inflammation RENAL

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Glasgow Royal Infirmary

    RECRUITING

    Glasgow, Scotland, G4 0SF, United Kingdom

  • Golden Jubilee National Hospital

    RECRUITING

    Glasgow, Scotland, G81 4DY, United Kingdom

  • Queen Elizabeth University Hospital

    RECRUITING

    Glasgow, Scotland, G51 4TF, United Kingdom

  • Royal Alexandra Hospital

    NOT_YET_RECRUITING

    Paisley, Scotland, PA2 9PN, United Kingdom

  • Royal Infirmary of Edinburgh

    RECRUITING

    Edinburgh, Scotland, EH16 4SA, United Kingdom

  • St John's Hospital

    RECRUITING

    Edinburgh, Scotland, EH54 6PP, United Kingdom

  • University Hospital Monklands

    RECRUITING

    Airdrie, Scotland, ML6 0JS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.